J07BK03 - Zoster, Purified Antigen |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the Purified antigen Zoster vaccine, no porphyrinogenic effects are expected.
Chemical description
Purified antigen.
Therapeutic characteristics
Indicated for protection against shingles (herpes zoster) and post-herpetic neuralgia in adults over the age of 50 or in adult over the age of 18 who are at increaced risk of herpes zoster. It is administered by intramuscular injections.
Metabolism and pharmacokinetics
Vaccines are not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | European Medicines Agency (EMA). SmPC Shingrix.
|
|
| 2. | Norwegian institute of public health. Vaccines and vaccination.
|
|
Tradenames
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Shingrix 
Vaccines